Reckitt Benckiser Group (RB) PT Lowered to GBX 5,800 at Credit Suisse Group

Reckitt Benckiser Group (LON:RB) had its target price reduced by research analysts at Credit Suisse Group from GBX 6,000 ($78.40) to GBX 5,800 ($75.79) in a report released on Tuesday. The brokerage currently has an “underperform” rating on the stock. Credit Suisse Group’s target price points to a potential downside of 2.59% from the stock’s current price.

Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. reissued an “overweight” rating and issued a GBX 9,000 ($117.60) price target on shares of Reckitt Benckiser Group in a report on Monday. Jefferies Financial Group set a GBX 5,000 ($65.33) price target on shares of Reckitt Benckiser Group and gave the company a “sell” rating in a report on Wednesday, February 6th. Liberum Capital reissued a “buy” rating and issued a GBX 7,300 ($95.39) price target on shares of Reckitt Benckiser Group in a report on Monday, February 4th. Royal Bank of Canada set a GBX 5,100 ($66.64) price target on shares of Reckitt Benckiser Group and gave the company a “sell” rating in a report on Wednesday, January 16th. Finally, UBS Group reissued a “neutral” rating and issued a GBX 6,400 ($83.63) price target (up from GBX 6,300 ($82.32)) on shares of Reckitt Benckiser Group in a report on Monday, January 14th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. Reckitt Benckiser Group presently has an average rating of “Hold” and a consensus price target of GBX 6,871.67 ($89.79).

RB opened at GBX 5,954 ($77.80) on Tuesday. Reckitt Benckiser Group has a 12 month low of GBX 5,562 ($72.68) and a 12 month high of GBX 8,110.43 ($105.98).

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers products for the treatment of analgesic and gastro-intestinal problems, sore throat, cough, pain, and flu, as well as wellness products in sexual wellbeing, footcare, vitamins, and supplements under the Durex, Gaviscon, Nurofen, Mucinex, Scholl/Amopé, and Strepsils brand names.

Featured Story: Price to Earnings Ratio (PE)

Analyst Recommendations for Reckitt Benckiser Group (LON:RB)

Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply